Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
Shanghai FTZ expedites cross-border transfer of specified data; CBP investigation finds no substantial evidence of evasion by CIE; and Another Chinese EV SPAC merger is in the pipeline but EU tariffs threaten the business.
Charles Wu of Clyde & Co describes the current regulatory state of China's investment market, for private equity investors, including the much anticipated recent clarity provided by key regulators as well as potential pitfalls to avoid
Successful U.S. IPO of Chinese EV brand suggests rising investor confidence, but regulatory risks still loom; Burberry wins trademark infringement and unfair competition lawsuit; and China proposes guidelines to it's lithium battery sector amid overcapacity concerns.
Surveillance camera maker Zhejiang Dahua exits U.S. market amid sanctions; China implements measures to boost mainland companies seeking to list in Hong Kong; and China rolls out measures to boost overseas investments in domestic sci-tech companies.
Na Wang and Yihui Liu, partners of Tian Yuan Law Firm, examine the Chinese securities regulator's key issues of concern with respect to overseas listings, and offer insights into the most recent regulatory trends
China designates four pilot areas for foreign investment into telecommunications without ownership caps; CFIUS may be allowed to request more information on transactions that were not filed with them; and CSRC proposes tighter controls on programme trading
